# Clotting Cascade: Coagulation Pathway Steps The clotting cascade is the ordered sequence of enzymatic reactions in which circulating inactive precursor proteins called zymogens are converted, one after another, into active enzymes that finally generate a cross-linked fibrin clot. It is traditionally divided into the intrinsic pathway (factors XII, XI, IX, VIII), the extrinsic pathway (tissue factor and factor VII), and the common pathway (factors X, V, II and I), all of which require calcium and a phospholipid surface to run efficiently. Understanding this system matters because bleeding and clotting disorders are among the most common emergencies in small animal practice. A dog with rodenticide poisoning, a cat with a suspected inherited coagulopathy, or a critically ill patient with disseminated intravascular coagulation all require the clinician to reason about which arm of the cascade has failed. The laboratory tests that screen for these problems, the activated partial thromboplastin time (APTT) and the prothrombin time (PT), are read directly against the pathway map. ## What Is the Clotting of Blood? Clotting of blood is the conversion of soluble plasma fibrinogen into an insoluble fibrin mesh that traps platelets and red cells to seal a vessel injury. The reaction is explosive once triggered, because each active enzyme in the cascade activates many molecules of the next factor, producing amplification at every step. The endpoint is always the same. Thrombin (activated factor II, written IIa) cleaves fibrinogen (factor I) into fibrin monomers, which polymerize and are then cross-linked by factor XIIIa into a stable clot. Everything upstream exists to generate enough thrombin at the right place and the right time. ## Why the Cascade Matters in Veterinary Practice Coagulation is a balance. Too little activity produces hemorrhage. Too much produces thrombosis, and the same patient can suffer both at once, as in disseminated intravascular coagulation. The cascade is also a major source of laboratory data. When a dog presents with unexplained bruising, the pattern of APTT and PT prolongation narrows the differential list before any specific factor assay is ordered. The cascade overlaps with inflammation, immunity and wound healing. Coagulation proteases activate receptors on platelets, endothelial cells and inflammatory cells, and the complement and coagulation systems share ancient evolutionary roots [1]. This crosstalk explains why severe systemic illness so often disturbs clotting tests. ## The Three Pathways at a Glance

| Feature | Intrinsic pathway | Extrinsic pathway | Common pathway | |--|--|--|--| | Trigger | Contact with a negatively charged surface | Tissue factor exposed at injury | Convergence of both arms | | Factors involved | XII, XI, IX, VIII | III (tissue factor), VII | X, V, II, I, XIII | | Key cofactor | Factor VIIIa | Tissue factor | Factor Va | | Screening test | APTT | PT | PT and APTT both prolonged | | Calcium required | Yes | Yes | Yes | | Phospholipid required | Yes | Yes | Yes | | Classic clinical example | Hemophilia A (factor VIII deficiency) | Rodenticide toxicity (factor VII first) | Warfarin-type poisoning, liver failure | ## The Intrinsic Pathway ### Step 1: Contact Activation The intrinsic pathway begins when factor XII contacts a negatively charged surface. In the test tube this surface is provided by kaolin, silica or ellagic acid. In the body, candidate surfaces include exposed collagen, activated platelet membranes and nucleic acids released from damaged cells. Factor XII autoactivates to XIIa on the surface. Factor XIIa then activates factor XI to XIa. Factor XIIa also activates prekallikrein to kallikrein, which feeds back to activate more factor XII, and the whole contact system is linked to the kallikrein-kinin system and to complement. A clinically important point follows from this: factor XII deficiency does not cause bleeding. Cats are the classic species in which factor XII activity is low or absent, and these cats are healthy and do not bleed. The APTT is markedly prolonged, which can mislead an unwary clinician into a bleeding disorder diagnosis when the real problem lies elsewhere. ### Step 2: Factor XI to IX Factor XIa, with calcium as a bridge, activates factor IX to IXa on the phospholipid surface. This step is the last one that is truly unique to the intrinsic arm. Once factor IXa is formed, the pathway converges on the common pathway through factor X. ### Step 3: The Tenase Complex Factor IXa is a weak enzyme on its own. It becomes a potent factor X activator only after binding factor VIIIa on a phospholipid membrane in the presence of calcium. This assembly is called the tenase complex, and it is the single most important amplification step in the intrinsic arm. Factor VIII circulates bound to von Willebrand factor, which stabilizes it. When factor VIII is missing or dysfunctional, the tenase complex cannot assemble efficiently, factor X activation collapses, and the patient has hemophilia A. The classic hemophiliac bleeding pattern is deep bleeding into joints and body cavities rather than the small surface hemorrhages seen with platelet disorders. Recent work has explored whether modified factor IX variants can bypass the need for factor VIII. Engineered FIX-FIAV variants showed normal factor IX specific activity and roughly fourfold enhanced factor VIII-equivalent clotting activity, and they retained normal activation by both the extrinsic (tissue factor and factor VIIa) and intrinsic (factor XIa) pathways [2]. These are experimental strategies, not current clinical treatments, but they illustrate how precisely the tenase interaction is understood. ## The Extrinsic Pathway ### Tissue Factor and Factor VII The extrinsic pathway is the physiological trigger for hemostasis after most tissue injuries. It starts when tissue factor (factor III), a [transmembrane protein](/blog/guides/transmembrane-protein) normally hidden from circulating blood, is exposed on subendothelial cells, fibroblasts and activated monocytes after vessel damage [3]. Factor VII circulates in plasma and binds exposed tissue factor. The tissue factor and factor VIIa complex is the most efficient activator of factor X known, and it also activates factor IX, providing a bridge between the two arms. Because factor VII has the shortest half-life of the vitamin K-dependent factors, it is the first to fall in warfarin-type anticoagulant poisoning, and the PT rises before the APTT. Tissue factor expression is not static. In anaphylaxis models, neutrophil extracellular trap formation was associated with tissue factor expression and coagulation abnormalities, and tissue factor pathway inhibitor modulated that signaling [3]. This shows that the extrinsic pathway can be recruited by inflammatory events, not only by mechanical injury. ### Why the Extrinsic Pathway Dominates In Vivo The classic teaching that the intrinsic and extrinsic arms are coequal contributors to hemostasis is not what happens in a living animal. In a study of patients undergoing liver transplantation, markers of intrinsic pathway activation rose during surgery, but markers of extrinsic activation stayed low even after adjustment for factor VII zymogen levels [4]. A separate study of COVID-19 patients found that median plasma factor VIIa levels were lower than the reference range, while factor XIIa and factor XIa levels were elevated, and the rise in factor XIIa tracked with the intensity of care [5]. The picture that emerges is that the contact (intrinsic) arm is more active than the textbooks suggest in systemic illness, while the tissue factor arm is tightly controlled. ## The Common Pathway ### Factor X to Thrombin Factor Xa, generated by either the tenase complex or the tissue factor and factor VIIa complex, binds factor Va on a phospholipid surface with calcium. This prothrombinase complex converts prothrombin (factor II) to thrombin (IIa) with extraordinary efficiency. Thrombin is the central enzyme of the cascade. It cleaves fibrinogen, activates factor XIII, activates factor V and factor VIII in positive feedback loops, and activates platelets. It also, once free in the circulation, binds thrombomodulin on intact endothelium and switches to an anticoagulant role by activating protein C. ### Fibrinogen to Fibrin Thrombin removes small peptides from the alpha and beta chains of fibrinogen, exposing polymerization sites. The resulting fibrin monomers assemble into a soft gel. Factor XIIIa, itself activated by thrombin in a calcium-dependent reaction, forms covalent cross-links between fibrin strands, producing a clot that resists plasmin digestion. Fibrinogen is also an acute phase protein, so its plasma concentration rises with inflammation. A high fibrinogen level can mask a mild bleeding tendency by producing a stronger clot, which is one reason clot strength tests and fibrinogen assays are interpreted together. ## Calcium, Phospholipid and the Reaction Surface Every step that involves a membrane-bound complex requires calcium. Calcium ions bridge the gamma-carboxyglutamate residues on the vitamin K-dependent factors to the negatively charged phospholipid head groups on the membrane. Phospholipid exposure is an active process. Phosphatidylserine normally sits on the inner leaflet of the cell membrane. When platelets or other cells activate, a phospholipase scramblase flips phosphatidylserine to the outer leaflet, creating the surface on which the tenase and prothrombinase complexes assemble. In dogs with immune-mediated hemolytic anemia, the most highly overexpressed gene in whole blood was a phospholipase scramblase, and this gene family is known to be critical for red cell death and for initiation of the clotting cascade [6]. That finding links red cell membrane changes directly to coagulation activation in a naturally occurring canine disease. This calcium and phospholipid requirement has practical consequences. Blood collected into EDTA, which chelates calcium, cannot clot. Blood collected into citrate is also calcium-depleted, and clotting is restored in the laboratory by adding calcium chloride. This is exactly what happens in the APTT and PT assays. ## The Vitamin K-Dependent Factors Four coagulation factors, II, VII, IX and X, plus the anticoagulant proteins C and S, require vitamin K for their synthesis. Vitamin K is a cofactor for gamma-glutamyl carboxylase, the enzyme that adds carboxyl groups to glutamate residues near the amino terminus of these proteins. Without carboxylation, the proteins are secreted but cannot bind calcium and cannot assemble on phospholipid surfaces. This single biochemical fact explains a large amount of clinical [veterinary medicine](/blog/careers/veterinary-medicine-careers-from-clinical-practice-to-public-health). Vitamin K antagonists used as rodenticides block the recycling of vitamin K, so the liver keeps producing nonfunctional factors II, VII, IX and X. Because factor VII has the shortest half-life, the PT prolongs first. As poisoning progresses, the APTT follows, and the patient bleeds. The same pathway explains why liver failure causes coagulopathy. The liver makes most coagulation factors, so synthetic failure produces a combined deficit that prolongs both PT and APTT. Protein C and protein S are the natural brakes on the system. Thrombin bound to thrombomodulin activates protein C, which with its cofactor protein S cleaves and inactivates factor Va and factor VIIIa. Protein C inhibitor is a separate regulator that inhibits both thrombin and activated protein C, and it sits at the junction of procoagulant and anticoagulant control [7]. A study of natural compounds found that naringin binds protein C inhibitor and alters its conformation, decreasing coagulation rates in the extrinsic and common pathways while increasing the rate in the intrinsic pathway [7]. That is a research finding, but it demonstrates that the anticoagulant arm can be modulated pharmacologically at the level of a single serpin. ## The Cell-Based Model of Coagulation The cascade as drawn on paper is a useful teaching map, but it does not describe what happens in a living blood vessel. Modern teaching places the cascade alongside the cell-based model, which organizes hemostasis into three overlapping phases. ### Initiation Tissue factor-bearing cells beneath the endothelium bind factor VIIa and generate small amounts of factor Xa and thrombin. This initial thrombin burst is tiny and stays localized. It is enough to activate platelets and factor V, VIII and XI, but not enough to clot the vessel. ### Amplification The small amount of thrombin generated in initiation activates platelets that have adhered to the injury site and activates factor V, factor VIII and factor XI on their surfaces. Platelets change shape, expose phosphatidylserine, and release granule contents. The stage is set for large-scale thrombin generation. ### Propagation Activated platelets now present the phospholipid surface on which the tenase and prothrombinase complexes assemble. Factor IXa generated by tissue factor and factor VIIa, plus factor IXa generated by factor XIa, drives a massive thrombin burst on the platelet surface. This is the thrombin that converts fibrinogen to fibrin and stabilizes the clot. The cell-based model explains several clinical puzzles. It explains why factor XII deficiency does not bleed: contact activation is not required for initiation or propagation. It explains why hemophilia is a bleeding disorder despite a normal extrinsic pathway: the tenase complex on the platelet surface is the engine of the thrombin burst. It also explains why thrombin generation assays, which measure the whole curve rather than a single clotting time, can detect abnormalities that APTT and PT miss. ## How the Cascade Is Tested in Practice ### APTT and PT The APTT tests the intrinsic and common pathways. A contact activator and phospholipid are added to citrated plasma, calcium is restored, and the time to clot formation is measured. The PT tests the extrinsic and common pathways. Tissue factor and phospholipid are added, calcium is restored, and the clotting time is recorded. Reference intervals differ between species. Dogs and cats have shorter APTT and PT reference ranges than humans, which reflects faster intrinsic clotting activity in these species. A value that would be normal in a person can be prolonged in a dog. Always interpret clotting times against species-specific and laboratory-specific reference intervals. ### Thrombin Generation Assays Thrombin generation assays measure the whole thrombin curve: lag time, peak height, time to peak and endogenous thrombin potential. A novel intrinsic trigger reagent developed for thrombin generation specifically activated the intrinsic pathway, showing minimal thrombin generation in factor XII and factor XI deficient plasma and no thrombin generation in factor IX and factor VIII deficient plasma [8]. This kind of reagent gives a more complete picture than APTT alone, especially in patients receiving non-factor replacement therapies where APTT is unreliable. ### Viscoelastic Testing Rotational thromboelastometry (ROTEM) and thromboelastography measure clot formation and lysis in whole blood. The INTEM channel assesses the intrinsic pathway, EXTEM assesses the extrinsic pathway, and FIBTEM assesses fibrinogen contribution. In a study of pediatric liver transplant recipients, most ROTEM parameters correlated strongly with the corresponding standard coagulation assays, though EXTEM clotting time and INR correlated less well [9]. These tests are increasingly used to guide transfusion in surgical and emergency patients. ### Factor Assays When a screening test is prolonged, specific factor activity assays identify the deficient factor. Factor VIII and factor IX assays confirm hemophilia A and B. Factor XII assay confirms the benign contact factor deficiency seen in cats. Mixing studies, in which patient plasma is mixed with normal plasma, distinguish factor deficiency from an inhibitor. ## Species Differences in the Clotting Cascade Cats and dogs differ from humans and from each other in ways that matter clinically. Cats have shorter APTT and PT reference ranges than humans. Factor XII deficiency is common in cats and is not associated with bleeding. A prolonged APTT in an otherwise healthy cat with no bleeding history should prompt consideration of factor XII deficiency before more invasive testing. Dogs also have shorter APTT and PT reference ranges than humans. Dogs develop immune-mediated hemolytic anemia far more often than humans, and the coagulation system is heavily involved. In a study of dogs with primary immune-mediated hemolytic anemia, genes related to neutrophil function, coagulation and hematopoiesis were overexpressed, and the most highly overexpressed gene was a phospholipase scramblase that externalizes phosphatidylserine and initiates the clotting cascade [6]. This makes the dog a naturally occurring model for studying the same disease in people. Rodenticide sensitivity varies with exposure and with the specific anticoagulant. All species are susceptible to vitamin K antagonist poisoning, and the laboratory pattern is the same: PT prolongs first, then APTT. ## Clinical Relevance, Limitations and Common Mistakes The cascade map is a tool for pattern recognition, not a complete physiological model. A prolonged APTT with a normal PT points to the intrinsic pathway. Consider hemophilia A or B, factor XI deficiency, or factor XII deficiency. In a cat with no bleeding, factor XII deficiency is the most likely explanation. A prolonged PT with a normal or mildly prolonged APTT points to the extrinsic pathway or early vitamin K antagonism. Rodenticide poisoning is the classic cause. Both prolonged points to the common pathway or to multiple factor deficiencies. Liver failure, disseminated intravascular coagulation and advanced vitamin K antagonism all produce this pattern. A normal APTT and PT does not exclude a bleeding disorder. Platelet function defects, von Willebrand disease, factor XIII deficiency and mild factor deficiencies can all produce bleeding with normal screening tests. The most common mistake is interpreting a prolonged APTT as proof of a bleeding disorder. Factor XII deficiency in cats is the classic trap. The second most common mistake is forgetting that reference intervals are species-specific. A third is assuming that the intrinsic and extrinsic arms contribute equally in vivo. The evidence from liver transplantation and from COVID-19 coagulopathy shows that the contact pathway can be highly active in systemic illness while the extrinsic pathway is suppressed [4][5]. Individual patients vary, and any animal with suspected bleeding or clotting disease needs evaluation by a veterinarian. This article is educational and is not a substitute for veterinary diagnosis or treatment. ## Quick Review 1. The clotting cascade has three arms: intrinsic (XII, XI, IX, VIII), extrinsic (III, VII) and common (X, V, II, I). 2. Every membrane-bound step requires calcium and a phosphatidylserine-exposing phospholipid surface. 3. Vitamin K is required for factors II, VII, IX and X, plus proteins C and S. 4. Factor VII has the shortest half-life, so PT prolongs before APTT in vitamin K antagonism. 5. Factor XII deficiency is common in cats and does not cause bleeding despite a prolonged APTT. 6. The cell-based model (initiation, amplification, propagation) explains in vivo hemostasis better than the cascade alone. 7. Dogs and cats have shorter APTT and PT reference ranges than humans. ## Frequently Asked Questions ### What is the clotting cascade in simple terms? The clotting cascade is a chain of enzyme activations in which each activated factor turns on the next, ending with thrombin converting fibrinogen into fibrin. The chain is divided into intrinsic, extrinsic and common pathways, and each step requires calcium and a phospholipid surface. ### Which pathway does the APTT test? The APTT tests the intrinsic and common pathways. A contact activator and phospholipid are added to citrated plasma, calcium is restored, and the time to clot is measured. ### Why do cats have prolonged APTT without bleeding? Many cats have low or absent factor XII activity. Factor XII is the first factor in the intrinsic pathway, so the APTT is prolonged, but factor XII is not required for hemostasis in vivo, so these cats do not bleed. ### What is the difference between the cascade model and the cell-based model? The cascade model is a test-tube map of factor interactions. The cell-based model describes what happens on cell surfaces in a living vessel, in three phases called initiation, amplification and propagation. ### Which factors depend on vitamin K? Factors II, VII, IX and X, plus the anticoagulant proteins C and S, require vitamin K for gamma-carboxylation. Without it, they cannot bind calcium and cannot function. ### Why does the PT prolong before the APTT in rodenticide poisoning? Factor VII has the shortest half-life of the vitamin K-dependent factors. When vitamin K recycling is blocked, factor VII activity falls first, and the PT rises before the APTT. ```mermaid flowchart TD A[Vessel injury] --> B[Intrinsic pathway] A --> C[Extrinsic pathway] B --> D[Factor XII to XIIa] D --> E[Factor XI to XIa] E --> F[Factor IX to IXa] F --> G[Tenase complex with factor VIIIa] C --> H[Tissue factor binds factor VIIa] G --> I[Factor X to Xa] H --> I I --> J[Prothrombinase complex with factor Va] J --> K[Thrombin generation] K --> L[Fibrin clot formation] ``` ## Related Articles - [Autophagy Pathway: Steps, Mechanism, and Regulation](/knowledge/molecular-biology/autophagy-pathway) - [Apoptosis Pathway: Key Steps and Mechanisms](/knowledge/molecular-biology/apoptosis-pathway) - [Peripheral Blood Smear Evaluation: A Step-by-Step Guide](/knowledge/veterinary-medicine/clinical-pathology/peripheral-blood-smear-evaluation-guide) - [MAP Kinase Pathway: Steps, Components, and Regulation](/knowledge/molecular-biology/map-kinase-pathway) - [Dog Blood in Urine: Causes and Emergency Steps](/knowledge/veterinary-medicine/digestive-and-urinary-care/dog-blood-in-urine-causes-emergency-steps) - [Cat Diarrhea with Blood: Urgency and Next Steps](/knowledge/veterinary-medicine/vet-visit-decisions/cat-diarrhea-with-blood) - [Glycolysis Pathway: Steps and Where It Occurs](/knowledge/molecular-biology/glycolysis-pathway-steps-and-where-it-occurs) - [Pentose Phosphate Pathway: Steps and Functions](/knowledge/molecular-biology/pentose-phosphate-pathway-steps-and-functions) ## Sources 1. [Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways.](https://pubmed.ncbi.nlm.nih.gov/42143157/) 2. [Substitution-induced allosteric activation of coagulation factor IX as a potential alternative hemophilia A treatment strategy.](https://pubmed.ncbi.nlm.nih.gov/42617289/) 3. [Neutrophil extracellular trap-associated responses are associated with tissue factor expression and coagulation abnormalities during anaphylaxis.](https://pubmed.ncbi.nlm.nih.gov/42712464/) 4. [In vivo activation of coagulation during human liver transplantation is associated with activation of the intrinsic pathway: an observational cohort study.](https://pubmed.ncbi.nlm.nih.gov/40496847/) 5. [Involvement of the contact pathway in COVID-19 coagulopathy.](https://pubmed.ncbi.nlm.nih.gov/41206422/) 6. [RNA sequencing of whole blood in dogs with primary immune-mediated hemolytic anemia (IMHA) reveals novel insights into disease pathogenesis.](https://pubmed.ncbi.nlm.nih.gov/33091028/) 7. [Naringin binds and activates protein C inhibitor for enhanced inhibition of thrombin and activated protein C with implications in coagulation control.](https://pubmed.ncbi.nlm.nih.gov/41549726/) 8. [Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A.](https://pubmed.ncbi.nlm.nih.gov/42254461/) 9. [Comparing Rotational Thromboelastometry and Standard Coagulation Assays for Predicting Intraoperative Bleeding in Pediatric Liver Transplantation.](https://pubmed.ncbi.nlm.nih.gov/41552928/)